Parabilis’ US listing means the biotech IPO record has been broken twice in as many months as public listings continue hot ...

The Cambridge, Massachusetts-based biotech priced 33.5 million shares at $20 each, topping the $625 million raised by Kailera ...

Parabilis Medicines’ IPO has lived up to the hype—securing $670 million for the largest listing in the sector’s history. The ...

Oncology-focused drug company nabs $670 million in scorching stock-market debut.

Ben Zercher is a Senior Analyst at PitchBook covering biotech & pharma. Parabilis Medicines just broke the record for the ...

Parabilis Medicines is expecting to raise around $670 million in its public offering, with another $75 million in a ...

Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, ...

Parabilis Medicines priced its upsized IPO at $20 per share, raising $670 million above its expected range, with a $75 ...

In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech ...

June 9 (Reuters) - Drug developer Parabilis Medicines is targeting a valuation of up to nearly $2.3 billion in its upsized ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now ...